Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471741 | 0.84 | ALDH1A1 (0.48) | CYP2D6KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL2856031 | 0.81 | L3MBTL1 (0.62) | TSHRKMT2AMEN1 | |
| SCHEMBL2470391 | 0.80 | KDM4E (0.54) | CYP2D6KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL2468360 | 0.79 | GRIN2B (0.48) | CYP2D6TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL2469566 | 0.79 | GRIN2B (0.48) | CYP2D6TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL2468358 | 0.79 | GRIN2B (0.48) | CYP2D6TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL2473431 | 0.79 | TACR1 (0.55) | CYP2D6KMT2AMEN1ALDH1A1KCNH2 | |
| SCHEMBL2468481 | 0.78 | TSHR (0.57) | CYP2D6TSHR | |
| SCHEMBL2470869 | 0.77 | CYP2D6 (0.63) | CYP2D6TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL2469683 | 0.77 | ALDH1A1 (0.58) | CYP2D6KMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | CYP2D6 1945/4885TSHR 2555/4885KMT2A 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.